Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand, and
treat rare diseases, announced today that the first patient has
been enrolled in the international EFRONT Study, an observational
study to understand the prevalence of genetic mutations in patients
with frontotemporal dementia (FTD).
Leveraging CENTOGENE’s rare disease-centric Bio/Databank and
extensive network of 20,000 physicians, the study aims to enroll
and complete data-rich genetic testing for more than 3,000 FTD
patients at participating centers in Belgium, Germany, Greece,
Italy, Portugal, Spain, and Turkey.
"This clinical study is a landmark for FTD research,” said
Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. “We will
significantly accelerate the understanding of FTD and drive further
development of treatments. Throughout the study, we will continue
working together with patients, healthcare professionals, and
clinical sites to provide both initial diagnostic answers, as well
as drive long-term progress for understanding this disease.”
The observational EFRONT Study is being conducted with support
from Alector, Inc. Patients displaying the progranulin gene
mutation (FTD-GRN) will have the option to enroll in Alector’s
Phase 3 INFRONT-3 clinical trial of AL001, an investigational
therapeutic candidate designed to increase progranulin levels for
the treatment of frontotemporal dementia and other
neurodegenerative diseases.
This announcement represents another significant milestone in
CENTOGENE’s mission to enable the cure of 100 rare diseases within
the next 10 years. To learn more, visit:
https://www.centogene.com/virtual-investor-event
About Frontotemporal Dementia
Frontotemporal Dementia (FTD) is a rapidly progressing and
severe form of dementia found most frequently in patients under the
age of 65 at the time of diagnosis. It affects approximately
110,000 patients in the European Union and more than 50,000 in the
United States. Patients with a mutation in the progranulin gene
represent 5% to 10% of FTD patients, with many others having a
genetic cause of this disease. There are currently no approved
treatment options available for FTD patients.
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository with
over 3.9 billion weighted data points from approximately 600,000
patients representing over 120 different countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Forward-Looking Statement
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative worldwide economic conditions and ongoing instability and
volatility in the worldwide financial markets, the effects of the
COVID-19 pandemic on our business and results of operations,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE
Ben Legg
Corporate Communications
Ben.Legg@centogene.com
Lennart Streibel
Investor Relations
Investor.Relations@centogene.com
FTI Consulting
Robert Stanislaro
robert.stanislaro@fticonsulting.com
Rachel Kleiman
rachel.kleiman@fticonsulting.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jul 2023 to Jul 2024